Related references
Note: Only part of the references are listed.Upregulation of the long non-coding RNA SPRY4-IT1 indicates a poor prognosis and promotes tumorigenesis in ovarian cancer
Hongxia Li et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer
Nisha Nagarsheth et al.
CANCER RESEARCH (2016)
DNA Methyltransferases Inhibitors from Natural Sources
Clemens Zwergel et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints
Jun Wei et al.
NEURO-ONCOLOGY (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma
Irina V. Tiper et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
Hong Zheng et al.
CLINICAL CANCER RESEARCH (2016)
How do tumor cells respond to HDAC inhibition?
Andrea Newbold et al.
FEBS JOURNAL (2016)
HDAC5 controls the functions of Foxp3+ T-regulatory and CD8+ T cells
Haiyan Xiao et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Current status of immunotherapy
Susumu Suzuki et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2016)
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
Mark J. Selby et al.
PLOS ONE (2016)
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment
Hazem El-Osta et al.
ONCOTARGETS AND THERAPY (2016)
Epigenetic epidemiology as a tool to understand the role of immunity in chronic disease
Heather H. Nelson et al.
EPIGENOMICS (2016)
Histone deacetylase inhibitors as immunomodulators in cancer therapeutics
Li Shen et al.
EPIGENOMICS (2016)
miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
Shaohua Xu et al.
NATURE COMMUNICATIONS (2016)
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Douglas B. Johnson et al.
NATURE COMMUNICATIONS (2016)
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
Michiel Kroesen et al.
ONCOIMMUNOLOGY (2016)
Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk
Jing Li et al.
ONCOIMMUNOLOGY (2016)
Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer
Danila Valmori et al.
ONCOIMMUNOLOGY (2016)
Histone deacetylase inhibitors in hematological malignancies and solid tumors
Pusoon Chun
ARCHIVES OF PHARMACAL RESEARCH (2015)
Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways
Jianbin Zhang et al.
AUTOPHAGY (2015)
STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells
Yan Cheng et al.
BMC CANCER (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G
Edgardo D. Carosella et al.
EUROPEAN UROLOGY (2015)
Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway
Alessandra Leone et al.
FREE RADICAL BIOLOGY AND MEDICINE (2015)
Antibody-based immunotherapy of solid cancers: progress and possibilities
Christopher F. Nicodemus
IMMUNOTHERAPY (2015)
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Madhusoodanan Mottamal et al.
MOLECULES (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
K. Cao et al.
ONCOGENE (2015)
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Andreas D. Orskov et al.
ONCOTARGET (2015)
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
Daniela S. Thommen et al.
CANCER IMMUNOLOGY RESEARCH (2015)
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
David M. Woods et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma
H. Yang et al.
BRITISH JOURNAL OF CANCER (2015)
Epigenetic Control of Macrophage Shape Transition towards an Atypical Elongated Phenotype by Histone Deacetylase Activity
Mariana Cabanel et al.
PLOS ONE (2015)
Understanding the CD28/CTLA-4 (CD152) Pathway and Its Implications for Costimulatory Blockade
D. Gardner et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells
Chengwu Zeng et al.
BMC CANCER (2014)
Histone Deacetylase Inhibitors Modulate Interleukin 6-dependent CD4+ T Cell Polarization in Vitro and in Vivo
Rainer Glauben et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells
Aaron Arvey et al.
NATURE IMMUNOLOGY (2014)
The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells
Makoto Kurachi et al.
NATURE IMMUNOLOGY (2014)
Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation
Cheol-Hun Son et al.
RADIATION ONCOLOGY (2014)
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
KiBem Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
Huili Li et al.
ONCOTARGET (2014)
Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
Kunle Odunsi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells
Dominique N. Lisiero et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome
Benedetta Costantini et al.
HAEMATOLOGICA (2013)
The Polycomb Protein Ezh2 Regulates Differentiation and Plasticity of CD4+ T Helper Type 1 and Type 2 Cells
Damon J. Tumes et al.
IMMUNITY (2013)
Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma
Kelly A. Cycon et al.
IMMUNOLOGY (2013)
HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression
Pierre-Francois Cartron et al.
MOLECULAR ONCOLOGY (2013)
HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy
Byram W. Bridle et al.
MOLECULAR THERAPY (2013)
Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer
Je-In Youn et al.
NATURE IMMUNOLOGY (2013)
Expression and regulation of intergenic long noncoding RNAs during T cell development and differentiation
Gangqing Hu et al.
NATURE IMMUNOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Influence of histone deacetylase inhibitors and DNA-methyltransferase inhibitors on the NK cell-mediated lysis of pediatric B-lineage leukemia
Matthias Manuel Pfeiffer et al.
FRONTIERS IN ONCOLOGY (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients
Michael J. Kelly-Sell et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Transcriptional and Epigenetic Control of T Helper Cell Specification: Molecular Mechanisms Underlying Commitment and Plasticity
Yuka Kanno et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
The Human TLR Innate Immune Gene Family Is Differentially Influenced by DNA Stress and p53 Status in Cancer Cells
Maria Shatz et al.
CANCER RESEARCH (2012)
STATs Shape the Active Enhancer Landscape of T Cell Populations
Golnaz Vahedi et al.
CELL (2012)
Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer
Karrune V. Woan et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression
Lucas E. Rossi et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo
Brian R. Rosborough et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
An epigenetic silencing pathway controlling T helper 2 cell lineage commitment
Rhys S. Allan et al.
NATURE (2012)
Long non-coding RNAs and cancer: a new frontier of translational research?
R. Spizzo et al.
ONCOGENE (2012)
Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
Li Shen et al.
PLOS ONE (2012)
Histone Deacetylases 6 and 9 and Sirtuin-1 Control Foxp3+ Regulatory T Cell Function Through Shared and Isoform-Specific Mechanisms
Ulf H. Beier et al.
SCIENCE SIGNALING (2012)
Natural Innate and Adaptive Immunity to Cancer
Matthew D. Vesely et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29 (2011)
Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection
Thierry Roger et al.
BLOOD (2011)
Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2
Sonja Textor et al.
CANCER RESEARCH (2011)
Advances in Epigenetics and Epigenomics for Neurodegenerative Diseases
Irfan A. Qureshi et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2011)
Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells
Alessia Burocchi et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer
K. Ted Thurn et al.
FUTURE ONCOLOGY (2011)
Therapeutic vaccination for cancer immunotherapy Antigen selection and clinical responses
Astrid Geldmacher et al.
HUMAN VACCINES (2011)
Cancer Immunotherapy Comes of Age
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
NK Cell Recognition and Killing of Melanoma Cells Is Controlled by Multiple Activating Receptor-Ligand Interactions
Sara Morgado et al.
JOURNAL OF INNATE IMMUNITY (2011)
Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3+ T-Regulatory Cells
Edwin F. de Zoeten et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
The biology of cancer testis antigens: Putative function, regulation and therapeutic potential
Elisabetta Fratta et al.
MOLECULAR ONCOLOGY (2011)
Differentiation of Effector CD4 T Cell Populations
Jinfang Zhu et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
Oliver Goodyear et al.
BLOOD (2010)
Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line
Jennifer S. Waby et al.
MOLECULAR CANCER (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages
Sang-Bae Han et al.
ARCHIVES OF PHARMACAL RESEARCH (2009)
Chromatin structure and DNA methylation of the IL-4 gene in human TH2 cells
Samantha Santangelo et al.
CHROMOSOME RESEARCH (2009)
Epigenetics and T helper 1 differentiation
Thomas M. Aune et al.
IMMUNOLOGY (2009)
Acetylation of FoxO1 Activates Bim Expression to Induce Apoptosis in Response to Histone Deacetylase Inhibitor Depsipeptide Treatment
Yang Yang et al.
NEOPLASIA (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Molecular mechanisms of MHC class I abnormalities and APM components in human tumors
Barbara Seliger
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Inducing the T cell fates required for immunity
Steven L. Reiner
IMMUNOLOGIC RESEARCH (2008)
Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target
Dorothy K. Sojka et al.
IMMUNOLOGY (2008)
Epigenetics at the epicenter of modern medicine
Andrew P. Feinberg
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
T-Bet Dependent Removal of Sin3A-Histone Deacetylase Complexes at the Ifng Locus Drives Th1 Differentiation
Shaojing Chang et al.
JOURNAL OF IMMUNOLOGY (2008)
Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma
Takashi Murakami et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
How tumours escape mass destruction
T. J. Stewart et al.
ONCOGENE (2008)
Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells
A. Nazmul H. Khan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Epigenetic drugs as pleiotropic agents in cancer treatment:: Biomolecular aspects and clinical applications
Luca Sigalotti et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
Comprehensive epigenetic profiling identifies multiple distal regulatory elements directing transcription of the gene encoding interferon-γ
Jamie R. Schoenborn et al.
NATURE IMMUNOLOGY (2007)
Methylation of human microRNA genes in normal and neoplastic cells
Barbara Weber et al.
CELL CYCLE (2007)
Chromatin modifications and their function
Tony Kouzarides
CELL (2007)
Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma
Jared A. Gollob et al.
CLINICAL CANCER RESEARCH (2006)
Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: Immunotherapeutic implications
S Coral et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study
AV Maker et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
JS Ungerstedt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Discrete roles for histone acetylation in human T helper 1 cell-specific gene expression
A Morinobu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
The inducible costimulator plays the major costimulatory role in humoral immune responses in the absence of CD28
WK Suh et al.
JOURNAL OF IMMUNOLOGY (2004)
Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation
JG Herman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
GQ Phan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
DNA methylation, methyltransferases, and cancer
KD Robertson
ONCOGENE (2001)
Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors
WJ Magner et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
